Daniel Von Hoff
Professor of Medicine
University of Arizona, College of Medicine.
Translational Genomics Research Institute
United States of America
Biography
Daniel D. Von Hoff, M.D., F.A.C.P., is currently Physician in Chief and Director of Translational Research at TGen (Translational Genomics Research Institute) in Phoenix, Arizona. He is also Chief Scientific Officer for US Oncology and for HonorHealth's Clinical Research Institute. He is also a Clinical Professor of Medicine, University of Arizona. Dr. Von Hoff graduated from Carroll College and received his medical degree from Columbia University College of Physicians and Surgeons. He went on to complete his internship and residency in internal medicine at the University of California, San Francisco, and a fellowship in medical oncology at the National Cancer Institute. Von Hoff became a professor in the departments of medicine and cellular and structural biology at the University of Texas Health Science Center, San Antonio. In 1989, he became the founding director of the Institute for Drug Development at the Cancer Therapy and Research Center in San Antonio and 10 years later he became the director of the cancer center and professor of medicine at the University of Arizona.
Research Interest
Dr. Von Hoff's major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many of the agents we now use routinely, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib and others. At present, he and his colleagues are concentrating on the development of molecularly targeted therapies for patients with pancreatic and other advanced cancers.
Publications
-
Design and synthesis of fluoroquinophenoxazines that interact with human telomeric G-quadruplexes and their biological effects Mol Cancer Ther Dec;1(2):103-20. 2001
-
Small interfering RNA-mediated knockdown of PRL phosphatases results in altered Akt phosphorylation and reduced clonogenicity of pancreatic cancer cells Mol Cancer Ther Jan;7(1):202-10 2008
-
A Randomized Phase II Study of PX-12, an inhibitor of Thioredoxin in Patients With Advanced Cancer of the Pancreas Following Progression after a Gemcitabine-Containing Combination. Can Chemo Pharmacol, Epub ahead of Print] 2010
-
Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agents Semin Oncol Aug;33(4):513-20 2006
-
Pancreatic cancer--could it be that simple? A different context of vulnerability. Cancer Cell 7;16(1):7-8. 2009
-
Using biointelligence to search the cancer genome: an epistemological perspective on knowledge recovery strategies to enable precision medical genomics Oncogene 27 2:S58-66. 2009
